Source:http://linkedlifedata.com/resource/pubmed/id/11858906
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0030471,
umls-concept:C0030705,
umls-concept:C0033119,
umls-concept:C0034117,
umls-concept:C0037199,
umls-concept:C0205409,
umls-concept:C0205453,
umls-concept:C0293352,
umls-concept:C0370003,
umls-concept:C0441655,
umls-concept:C0442027,
umls-concept:C0450254,
umls-concept:C0533545,
umls-concept:C1136254,
umls-concept:C1305231,
umls-concept:C1510824,
umls-concept:C1533691,
umls-concept:C1707455
|
pubmed:issue |
2
|
pubmed:dateCreated |
2002-3-7
|
pubmed:abstractText |
Using a microbroth method for aerobes and agar dilution for anaerobes, we studied the comparative in vitro activity of gemifloxacin, three fluoroquinolones, two macrolides and two beta-lactams, against 207 aerobic and 162 anaerobic antral sinus puncture isolates. Gemifloxacin was active at < or = 0.25 ug/mL against 198/207 [96%] aerobes and 127/162 [78%] anaerobes or 325/369 [88%] of all isolates and was the most active quinolone on a weight basis against Gram-positive organisms. All Haemophilus and Moraxella species were susceptible to < or =0.06 ug/mL of gemifloxacin. Thirty-five anaerobic isolates [35/162, 22%] required > or =0.5 ug/mL of gemifloxacin for inhibition, including all Prevotella species [all except one strain of P. bivia were susceptible to < or = 2 ug/mL] and occasional strains of Bacteroides uniformis, Bacteroides fragilis, Bilophila wadsworthia, Peptostreptococcus magnus, Peptostreptococcus micros, Propionibacterium acnes, and Veillonella species. All fusobacteria were susceptible to < or =0.25 ug/mL of gemifloxacin. Based on our in vitro study results, we conclude that gemifloxacin may offer a therapeutic alternative for sinus infections.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthyridines,
http://linkedlifedata.com/resource/pubmed/chemical/gemifloxacin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0732-8893
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
113-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11858906-Anti-Bacterial Agents,
pubmed-meshheading:11858906-Anti-Infective Agents,
pubmed-meshheading:11858906-Bacteria, Aerobic,
pubmed-meshheading:11858906-Bacteria, Anaerobic,
pubmed-meshheading:11858906-Drug Resistance, Bacterial,
pubmed-meshheading:11858906-Fluoroquinolones,
pubmed-meshheading:11858906-Humans,
pubmed-meshheading:11858906-Maxillary Sinus,
pubmed-meshheading:11858906-Microbial Sensitivity Tests,
pubmed-meshheading:11858906-Naphthyridines,
pubmed-meshheading:11858906-Punctures,
pubmed-meshheading:11858906-Sinusitis
|
pubmed:year |
2002
|
pubmed:articleTitle |
In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
|
pubmed:affiliation |
R.M. Alden Research Laboratory, Santa Monica-UCLA Medical Center, Santa Monica, CA 90404, USA. EJCGMD@aol.com
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|